Werewolf Therapeutics, Inc. (HOWL)
NASDAQ: HOWL · IEX Real-Time Price · USD
2.950
+0.090 (3.15%)
Jul 16, 2024, 4:00 PM EDT - Market closed

Werewolf Therapeutics Income Statement

Millions USD. Fiscal year is Jan - Dec.
Year Ending
TTM Dec 31, 2023Dec 31, 2022Dec 31, 2021Dec 31, 2020Dec 31, 2019
Revenue
16.2219.9416.4000
Revenue Growth (YoY)
-22.26%21.60%----
Gross Profit
16.2219.9416.4000
Selling, General & Admin
18.6918.6718.714.825.763.6
Research & Development
42.9841.7853.7635.2716.646.34
Operating Expenses
61.6660.4572.4650.0922.49.94
Operating Income
-45.44-40.5-56.06-50.09-22.4-9.94
Interest Expense / Income
4.143.140000.37
Other Expense / Income
-8.01-6.27-2.25-0.1-7.36-0.06
Pretax Income
-41.58-37.37-53.81-49.98-15.04-10.25
Net Income
-41.58-37.37-53.81-49.98-15.04-10.25
Preferred Dividends
000151.9413.187.98
Net Income Common
-41.58-37.37-53.81-201.93-28.22-18.23
Shares Outstanding (Basic)
4236291811
Shares Outstanding (Diluted)
4236291811
Shares Change
19.61%23.50%56.40%1736.32%57.06%-
EPS (Basic)
-1.09-1.05-1.86-10.94-28.08-28.49
EPS (Diluted)
-1.09-1.05-1.86-10.94-28.08-28.49
Free Cash Flow
-38.72-33.38-44.21-43.37-19.18-9.81
Free Cash Flow Per Share
-0.93-0.94-1.53-2.35-19.09-15.33
Gross Margin
100.00%100.00%100.00%---
Operating Margin
-280.14%-203.09%-341.78%---
Profit Margin
-256.33%-187.37%-328.09%---
Free Cash Flow Margin
-238.72%-167.38%-269.54%---
EBITDA
-34.02-30.89-51.3-49.25-14.26-9.41
EBITDA Margin
-209.72%-154.89%-312.79%---
Depreciation & Amortization
3.423.342.510.740.780.46
EBIT
-37.44-34.23-53.81-49.98-15.04-9.88
EBIT Margin
-230.79%-171.63%-328.09%---
Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).